Research programme: SPLP gene therapies - ProtivaAlternative Names: Pro-101; Pro-41; Pro-Alpha; Pro-Beta; SPLP gene therapy research programme - Protiva
Latest Information Update: 18 May 2009
At a glance
- Originator Protiva Biotherapeutics
- Class Gene therapies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 May 2009 Discontinued - Preclinical for Cancer in Canada (IV)
- 17 Jun 2003 Pro 1 has advanced from this research programme into clinical development
- 07 Feb 2001 Preclinical development for Cancer in Canada (IV)